Improved detection of recurrent bladder cancer using the Bard BTA stat Test Journal Article


Authors: Sarosdy, M. F.; Hudson, M. A.; Ellis, W. J.; Soloway, M. S.; White, R. D.; Sheinfeld, J.; Jarowenko, M. V.; Schellhammer, P. F.; Schervish, E. W.; Patel, J. V.; Chodak, G. W.; Lamm, D. L.; Johnson, R. D.; Henderson, M.; Adams, G.; Blumenstein, B. A.; Thoelke, K. R.; Pfalzgraf, R. D.; Murchison, H. A.; Brunelle, S. L.
Article Title: Improved detection of recurrent bladder cancer using the Bard BTA stat Test
Abstract: Objectives. To evaluate the BTA stat Test in the detection of recurrent bladder cancer. Methods. Sensitivity and specificity were determined using frozen voided urine samples from patients with recurrent bladder cancer, volunteers, patients with nonurologic conditions, and patients with a history of bladder cancer but free of disease. Results of cytology and the original BTA Test were compared with the sensitivity of the BTA stat Test in a large subgroup of the patients with cancer. Results. The BTA stat Test detected 147 (57%) of 220 recurrent cancers. For those urine samples with previous cytologic and BTA Test results available, cytology had a sensitivity of 23%, the BTA Test 44%, and the BTA stat Test 58% for detection of recurrent cancer (P < 0.001, stat versus cytology). The specificity of the BTA stat Test was 72% for benign genitourinary disease and 95% in healthy volunteers. Conclusions. The BTA stat Test has high sensitivity and is significantly superior to voided urine cytologic analysis in the detection of recurrent bladder cancer. (C) 1997, Elsevier Science Inc. All rights reserved.
Journal Title: Urology
Volume: 50
Issue: 3
ISSN: 0090-4295
Publisher: Elsevier Science, Inc.  
Date Published: 1997-09-01
Start Page: 349
End Page: 353
Language: English
ACCESSION: WOS:A1997XW20100006
DOI: 10.1016/s0090-4295(97)00292-6
PROVIDER: wos
PUBMED: 9301696
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Joel Sheinfeld
    254 Sheinfeld